HIMS
Peptides are back in the chat
Hims & Hers is riding a new wave of momentum after the FDA said it plans to hold a July meeting that could loosen restrictions on peptide injections. In plain English: one of the key regulatory potholes in the company’s compounding playbook may be getting a little less jagged.
Why investors care
This matters because Hims has been leaning into compounded peptide treatments — especially the kind marketed around weight loss, hair loss, and other buzzy wellness trends. The company even bought a factory in February to make peptides domestically, basically telling Wall Street, “We’re not just renting a booth at the party, we’re bringing the DJ.”
The stock isn’t just running on vibes
The move got an extra boost from BofA Securities analyst Allen Lutz, who kept a neutral rating but lifted his price target from $21 to $25. That’s not exactly a bear hug, but it is a mild vote of confidence.
The catch
HIMS has already had a monster run, so the chart is now flashing some “don’t get too comfortable” signals. The stock was up 9.6% to $29.58, and momentum looks strong — maybe a little too strong — with RSI nearing overbought territory.
Big picture: Hims doesn’t need a miracle here, just a regulatory breeze. If the FDA actually loosens the rules, the company’s peptide ambitions get a cleaner runway. If not, this rally may turn out to be another caffeine-fueled sprint.